Table 3.
Summary of Key Results
| Sample Size (%) | |
|---|---|
| Total number of participants | 2,481,887 |
| Number of healthcare workers | 945 (0.3%) |
| Number of older adults | 2,480,9422,481,887 (99.7%) |
| Number of studies included | n = 39 |
| Study Location | |
| United States | 30/39 (76.9%) |
| Singapore | 3/39 (7.7%) |
| Japan | 2/39 (5.1%) |
| Canada | 1/39 (2.6%) |
| Hong Kong | 1/39 (2.6%) |
| Australia | 1/39 (2.6%) |
| Germany | 1/39 (2.6%) |
| Study Design | |
| Interventional | 34/39 (87.2%) |
| Controlled | 15/34 (44.1%) |
| Randomized | 5/34 (14.7%) |
| Observational | 5/39 (12.8%) |
| Type of pneumococcal vaccine | |
| PPV23 | 7/39 (17.9%) |
| PVC13 | 1/39 (2.6%) |
| Both PVC13 and PPV23 | 14/39 (35.8%) |
| Outcome Measures | |
| Vaccination rates | n = 34 |
| Information or awareness scores | n = 9 |
| Implementation outcomes | n = 6 |
| Pillar according to European Union Conceptional Framework for Action | |
| Information campaigns | n = 15 |
| Prioritization of vaccination schemes | n = 14 |
| Primary care interventions | n = 10 |